IPHA
Innate Pharma SA Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website innate-pharma.com
- Employees(FY) 191
- ISIN US45781K2042
Performance
+8.09%
1W
+4.63%
1M
+6.69%
3M
+14.34%
6M
-3.22%
YTD
-10.27%
1Y
Profile
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Technical Analysis of IPHA 2024-05-10
Overview:
In analyzing the technical indicators for IPHA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2023-10-15 13:00
- 2023-10-08 13:00
- 2023-10-04 13:00
- 2023-09-21 13:00
- 2023-09-13 13:00
- 2023-08-28 13:00
- 2023-08-09 13:00
Innate Pharma to Participate in Upcoming Investor Conference(Yahoo Finance)
- 2023-07-10 13:00
- 2023-07-06 13:00
- 2023-06-25 13:00
- 2023-06-25 13:00
- 2023-06-15 13:00
- 2023-06-11 13:00
- 2023-06-09 13:00
- 2023-06-07 13:00
- 2023-06-07 13:00
- 2023-06-06 13:00
- 2023-05-25 13:00
- 2023-05-22 13:00
- 2023-05-14 13:00
- 2023-05-12 04:00
Outcome of Innate Pharmas 2023 Annual General Meeting(Yahoo Finance)
- 2023-05-09 13:00
- 2023-05-08 13:00
- 2023-05-02 13:00
- 2023-05-02 13:00
- 2023-04-26 04:50
- 2023-04-20 13:00
Innate Pharma to Participate in Upcoming Investor Conference(Yahoo Finance)
- 2023-04-17 13:00
- 2023-04-06 13:00
- 2023-04-05 13:00